These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 2500615)

  • 21. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease.
    Baggio B; Gambaro G; Favaro S; Borsatti A
    Nephron; 1983; 35(1):11-4. PubMed ID: 6888620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary excretion of uricine.
    Pinto B; Rocha E
    Invest Urol; 1977 Sep; 15(2):155-7. PubMed ID: 20424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does urine from stone-formers contain macromolecules which promote the crystal growth rate of calcium oxalate crystals in vitro?
    Gjaldbaek JC; Robertson WG
    Clin Chim Acta; 1980 Nov; 108(1):75-80. PubMed ID: 6778638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dietary control of urinary uric acid excretion in calcium oxalate stone formers and non-stone-forming controls.
    Pais VM; Holmes RP; Assimos DG
    J Endourol; 2007 Feb; 21(2):232-5. PubMed ID: 17338626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers.
    Srinivasan S; Kalaiselvi P; Sakthivel R; Pragasam V; Muthu V; Varalakshmi P
    Clin Chim Acta; 2005 Mar; 353(1-2):45-51. PubMed ID: 15698589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary inhibitory activity of calcium oxalate monohydrate crystal growth in stone-formers & non stone-formers.
    Sidhu H; Vaidyanathan S; Wangoo D; Rattan V; Thind SK; Nath R; Malakondaiah GC; Tandon SP
    Indian J Med Res; 1987 Oct; 86():500-5. PubMed ID: 3443483
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference?
    Tefekli A; Esen T; Ziylan O; Erol B; Armagan A; Ander H; Akinci M
    Urol Int; 2003; 70(4):273-7. PubMed ID: 12740490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis.
    Takasaki E
    Invest Urol; 1975 Jan; 12(4):251-4. PubMed ID: 1112654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of GAGS on 24-hour and 2-hour urines from calcium oxalate stone formers and healthy subjects.
    Gianotti M; Genestar C; Palou A; Pons A; Conte A; Grases F
    Int Urol Nephrol; 1989; 21(3):281-8. PubMed ID: 2807779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uric acid-binding proteins in calcium oxalate stone formers and their effect on calcium oxalate crystallization.
    Kalaiselvi P; Udayapriya KL; Selvam R
    BJU Int; 1999 Jun; 83(9):919-23. PubMed ID: 10368229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the possible role of glycosaminoglycans as natural inhibitors of calcium oxalate stones.
    Sallis JD; Lumley MF
    Invest Urol; 1979 Jan; 16(4):296-9. PubMed ID: 429124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The influence of uric acid on the calcium oxalate stone formation (author's transl)].
    Matouschek E; Huber R
    Urologe A; 1979 Jul; 18(4):211-4. PubMed ID: 38552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical studies of the recurrence of urolithiasis (3). Influence of sodium intake on urinary excretion of calcium, uric acid, oxalate, phosphate and magnesium].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1988 Sep; 34(9):1537-41. PubMed ID: 3213789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The most important metabolic risk factors in recurrent urinary stone formers.
    Parvin M; Shakhssalim N; Basiri A; Miladipour AH; Golestan B; Mohammadi Torbati P; Azadvari M; Eftekhari S
    Urol J; 2011; 8(2):99-106. PubMed ID: 21656467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of diclofenac-Na on 24-hour urinary excretion of creatinine, calcium, uric acid and glycosaminoglycans in adult patients with recurrent calcium oxalate nephrolithiasis.
    Hemal AK; Sidhu H; Thind SK; Nath R; Vaidyanathan S
    Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):44-6. PubMed ID: 2744906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current status of prevention and therapy of urinary calculi and peroral chemo-litholysis with special attention to the relationship of increased excretion of uric acid in oxalate lithiasis].
    Leskovar P
    Z Urol Nephrol; 1980 Mar; 73(3):229-39. PubMed ID: 7434987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of mucopolysaccharide elimination in urolithiasis].
    Hesse A; Hartmann U; Schneider HJ; Horn G
    Z Urol Nephrol; 1975 Jun; 70(6):401-5. PubMed ID: 127480
    [No Abstract]   [Full Text] [Related]  

  • 38. Electrophoretic separation and characterization of urinary glycosaminoglycans and their roles in urolithiasis.
    Gohel MD; Shum DK; Tam PC
    Carbohydr Res; 2007 Jan; 342(1):79-86. PubMed ID: 17145044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of diclofenac sodium on urinary concentration of calcium, uric acid and glycosaminoglycans in traumatic paraplegics.
    Sharma S; Vaidyanathan S; Thind SK; Nath R; Sankaranarayanan A
    Br J Urol; 1991 Sep; 68(3):240-2. PubMed ID: 1913063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hyperuricosuric calcium oxalate stone former.
    Sarig S
    Miner Electrolyte Metab; 1987; 13(4):251-6. PubMed ID: 3306317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.